Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
10 pending office actions • 10 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Health Research Inc. is currently managing 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 10 distinct art units, which indicates a high level of technical diversity within the company's pharmaceutical research. The company is also dealing with 10 distinct examiners, meaning that every active office action is being reviewed by a different individual. This distribution suggests that the company's research and development efforts span multiple specialized biological disciplines.
WIEST, PHILIP R is identified as the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because each of the 10 distinct examiners is handling exactly one case, the workload is perfectly distributed across the involved personnel. For practitioners, this means there is no central examiner to influence the majority of the portfolio. Instead, ten separate prosecution tracks must be managed across 10 distinct art units, requiring a diverse set of arguments to satisfy ten different examiners. The data shows a balanced interaction with the patent office where each of the 10 pending office actions is treated as a unique technical and legal matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 4 (40%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WIEST, PHILIP R | 1 | 81.5% | +16.1% |
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.2% | +38.9% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| HELLMAN, KRISTINA M | 1 | 65.1% | +55.5% |
| MULLINS, JESSICA LYNN | 1 | 50.5% | +33.5% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| FONSECA LOPEZ, FRANCINI ALVARENGA | 1 | 28.6% | +30.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19102821 | LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX | WIEST, PHILIP R | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | RZECZYCKI, PHILLIP MATTHEW | 60d overdue |
| 17523079 | ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES | FONSECA LOPEZ, FRANCINI ALVARENGA | 34d |
| 18439315 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | REDDIG, PETER J | — |
| 18162995 | METHOD AND SYSTEM FOR CONCURRENT PHOTOTHERMAL ABLATION AND INTERSTITIAL PHOTODYNAMIC THERAPY | MULLINS, JESSICA LYNN | — |
| 17638518 | REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD) | HUDSON, AMY ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | RZECZYCKI, PHILLIP MATTHEW | 60d overdue |
| 17523079 | ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES | FONSECA LOPEZ, FRANCINI ALVARENGA | 34d |
| 19102821 | LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX | WIEST, PHILIP R | — |
| 18708140 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | JONES-FOSTER, ERICA NICOLE | — |
| 18691035 | METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS | PAGUIO FRISING, MICHELLE F | — |
| 18439315 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | REDDIG, PETER J | — |
| 18259763 | ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES | PETERS, ALEC JON | — |
| 18249816 | SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 3781 | 1 |
| 1656 | 1 |
| 1651 | 1 |
| 1642 | 1 |
| 1641 | 1 |
| 1625 | 1 |
| 1654 | 1 |
| 3792 | 1 |
| 1636 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19102821 | LOCK TO POLE BIOMETRIC ACCESS INTRAVENEOUS MEDICATION LOCKBOX | WIEST, PHILIP R | 3781 | §103 | Non-Final OA | — | Pending | Feb 10, 2025 |
| 18708140 | DEPLETING EGFR AND HER2 OVERCOMES RESISTANCE TO EGFR INHIBITORS IN COLORECTAL CANCER | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | — | Pending | May 07, 2024 |
| 18691035 | METHOD OF MITIGATION OF INJURIES CAUSED BY SYSTEMIC GENOTOXIC STRESS | PAGUIO FRISING, MICHELLE F | 1651 | §112 | Non-Final OA | — | Pending | Mar 11, 2024 |
| 18439315 | METHOD FOR PROPHYLAXIS AND/OR TREATMENT OF ErbB2 POSITIVE CANCERS | REDDIG, PETER J | 1642 | §101§102§103DP | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18259763 | ANTI-SURVIVIN ANTIBODIES FOR TREATMENT OF AUTOIMMUNE DISEASES | PETERS, ALEC JON | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102§112 | Final Rejection | 60d overdue | Pending | May 17, 2023 |
| 18249816 | SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES | HELLMAN, KRISTINA M | 1654 | §103 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18162995 | METHOD AND SYSTEM FOR CONCURRENT PHOTOTHERMAL ABLATION AND INTERSTITIAL PHOTODYNAMIC THERAPY | MULLINS, JESSICA LYNN | 3792 | §102§103 | Non-Final OA | — | Pending | Feb 01, 2023 |
| 17638518 | REACTIVATING P53 MUTANTS FOR CANCER TREATMENT BY TARGETING PROLIDASE (PEPD) | HUDSON, AMY ROSE | 1636 | §103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17523079 | ANTI-MICROBIAL PEPTIDES AND METHOD FOR DESIGNING NOVEL ANTI-MICROBIAL PEPTIDES | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §103 | Final Rejection | 34d | Pending | Nov 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHealth Research Inc. has 10 pending office actions as of October 2026, spread across 10 art units and 10 examiners.
Philip R Wiest has the most, with 1 of Health Research Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
